Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update

Author's Avatar
Feb 27, 2019
Article's Main Image

On track to select optimal dose of AT132 for the treatment of XLMTM in the second quarter of 2019, and gain final agreement on BLA and MAA submission pathways in the third quarter of 2019

On track to submit an Investigational New Drug (IND) application for AT845 for Pompe Disease in the third quarter of 2019

Strong balance sheet with December 31, 2018 cash, cash equivalents, marketable securities, and restricted cash of $418.1 million, expected to fund operations into 2021

PR Newswire